RxDoctor Payments DataLook up a doctor →

Kara Way, MD

Neurology · Hot Springs, ARNPI 1982047940

Payments from drug & device makers

$71,733in general payments, 2019–2025

Across 760 payments — averaging $94.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$21K
  • Pfizer$19K
  • Biohaven Pharmaceutical Holding Company Ltd.$19K
  • AbbVie$2K
  • Novartis$2K
  • MDD US Operations, LLC$988
  • plus $8K from 47 others

What the payments were for

  • Consulting fees$2,4653%
  • Speaking & faculty fees$51,60172%
  • Travel & lodging$3,2785%
  • Food & beverage$14,37820%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,733 in reported general payments places this provider in the 90th percentile of 93 neurology providers in Arkansas.

See all neurology providers in Arkansas

Medicare billing

Part B allowed, 2024
$131,802
Medicare patients
516
Services billed
7,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4649$515,532
PanzygaImmun Glob G(Igg)-Ifas/Glycine15$172,743
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$160,159
VumerityDiroximel Fumarate18$155,980
Nurtec OdtRimegepant Sulfate90$117,129
QuliptaAtogepant68$72,275
Aimovig AutoinjectorErenumab-Aooe43$72,002
Emgality PenGalcanezumab-Gnlm49$51,347
BotoxOnabotulinumtoxina24$31,446
UbrelvyUbrogepant21$21,897
RytaryCarbidopa/Levodopa12$21,452
BriviactBrivaracetam11$15,150
Carbidopa-LevodopaCarbidopa/Levodopa283$6,875
Gabapentin222$3,609
Levetiracetam152$3,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kedrion Biopharma, Inc.Gammaked$66$515,53249 claims
PfizerPanzyga, Nurtec Odt$18,594$289,872105 claims
BiogenVumerity$618$155,98018 claims
AbbVieQulipta, Botox, Ubrelvy$2,233$125,617113 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$962$22,52835 claims
UCB, Inc.Briviact$444$15,15011 claims
Upsher-smith Laboratories LLCTopiramate$30$82586 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 93 neurology providers in Arkansas.

Other neurology in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →